Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778633 | 0.81 | AHR (0.41) | AHRCYP2A6NR4A2PIM3CHEK1 | |
| SCHEMBL11101358 | 0.79 | KMT2A (0.41) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL23735763 | 0.78 | USP2 (0.41) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL21921427 | 0.78 | AHR (0.41) | AHRNR4A2CHEK1BRD4TAF1 | |
| SCHEMBL31265094 | 0.78 | REN (0.38) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL27778491 | 0.77 | AHR (0.35) | AHRCYP2A6NR4A2PIM3CHEK1 | |
| SCHEMBL24165715 | 0.75 | MEN1 (0.43) | CYP2A6HTR2AHTR2CIKBKBCHUK | |
| SCHEMBL27778480 | 0.75 | AHR (0.33) | AHRCYP2A6NR4A2CHEK1HTR2A | |
| SCHEMBL3584001 | 0.75 | AHR (0.45) | AHRCYP2A6NR4A2PIM3BRD4 | |
| SCHEMBL8995163 | 0.74 | AHR (0.48) | AHRCYP2A6NR4A2PIM3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| US-7446122-B2 | Substituted indole derivatives | CEPHALON, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7314886-B2 | Tetrahydropyrano-indole derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | AHR 37/4885CYP2A6 205/4885NR4A2 2417/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | AHR 153/4885CYP2A6 141/4885NR4A2 961/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | AHR 271/4885CYP2A6 202/4885NR4A2 839/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | AHR 271/4885CYP2A6 202/4885NR4A2 839/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | AHR 271/4885CYP2A6 202/4885NR4A2 839/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | AHR 515/4885CYP2A6 4401/4885NR4A2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.